BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial

Abstract Relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD) represents a challenging condition, with limited treatment options and poor prognosis. We conducted a phase 1 clinical trial to evaluate the safety and effectiveness of a novel bispecific chimeric antigen receptor...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Journal of Hematology & Oncology
المؤلفون الرئيسيون:	Hao Yao, Shi-hui Ren, Lin-hui Wang, Ming-qiang Ren, Jiao Cai, Dan Chen, Ying He, Si-han Lai, Bai-tao Dou, Meng-jiao Li, Yan-ling Li, Ya-li Cen, Alex H. Chang, Yi Su, Ling Qiu, Fang-yi Fan
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	BMC 2025-05-01
الموضوعات:	BCMA GPRC5D CAR T-cell therapy Relapsed/refractory multiple myeloma Extramedullary disease Immunotherapy
الوصول للمادة أونلاين:	https://doi.org/10.1186/s13045-025-01713-2